ALNY Q2 Earnings Top Estimates on Higher Amvuttra Revenues, Stock UpZacks Investment Research • 08/01/25
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat ForecastBenzinga • 07/31/25
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat EstimatesZacks Investment Research • 07/31/25
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period ProgressBusiness Wire • 07/31/25
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseZacks Investment Research • 07/24/25
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial ResultsBusiness Wire • 07/17/25
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development OfficerBusiness Wire • 06/18/25
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with CardiomyopathyBusiness Wire • 06/09/25
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare ConferenceBusiness Wire • 05/28/25
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-BBusiness Wire • 05/17/25
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 CongressBusiness Wire • 05/12/25
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care ConferenceBusiness Wire • 05/05/25